HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yerby, M. S. Search for Related Content PubMed PubMed Citation Articles by Yerby, M. S.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Management issues for women with epilepsy

Neural tube defects and folic acid supplementation

From the Departments of Obstetrics and Gynecology, Public Health and Preventive Medicine, Oregon Health & Science University, North Pacific Epilepsy Research Center, Portland, OR.

Address correspondence and reprint requests to Dr. Mark S. Yerby, Departments of Obstetrics and Gynecology, Public Health and Preventive Medicine, Oregon Health & Science University, North Pacific Epilepsy Research Center, 2455 NW Marshall Street, Suite 14, Portland, OR 97201.

For infants exposed to antiepileptic drugs (AEDs) in utero, the risk for congenital malformations is approximately 4 to 6%, twice the rate reported in the general population. A variety of malformations have been reported in association with prenatal exposure to AEDs. However, a particular association of valproate and carbamazepine with neural tube defects (NTDs)—specifically, with spina bifida aperta (SB)—has been identified. The prevalence of SB is approximately 1 to 2% with valproate exposure and 0.5% with carbamazepine. Reported risk factors for NTDs include previous pregnancy with an NTD, maternal insulin-dependent diabetes mellitus, various nutritional deficiencies and occupational exposures, and high prepregnancy weight. Deficiencies of folate have been implicated in the development of birth defects, including NTDs. The value of periconceptional folic acid supplementation for women in the general population is accepted. However, it is unclear whether folic acid supplementation protects against the embryotoxic and teratogenic effects of AEDs because animal and human studies and case reports have shown variable results. Nevertheless, folic acid supplementation is recommended for women with epilepsy as it is for other women of childbearing age. Even with supplementary folic acid, women taking valproate or carbamazepine should undergo perinatal diagnostic ultrasound to rule out NTDs.

This article has been cited by other articles:

				U.S. Preventive Services Task Force Folic Acid for the Prevention of Neural Tube Defects: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, May 5, 2009; 150(9): 626 - 631. [Abstract] [Full Text] [PDF]

				G. Montouris Importance of monotherapy in women across the reproductive cycle Neurology, December 11, 2007; 69(24_suppl_3): S10 - S16. [Abstract] [Full Text] [PDF]

				M D O'Brien and S K Gilmour-White Management of epilepsy in women Postgrad. Med. J., May 1, 2005; 81(955): 278 - 285. [Abstract] [Full Text] [PDF]

Correspondence: